Investigational drug · Phase 2
GSK5926371
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lymphoma, Non-Hodgkin.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "GSK5926371"
First trial start
2026
Jun 19, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GSK5926371", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lymphoma, Non-Hodgkin
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "GSK5926371" as an intervention, largest first.
GlaxoSmithKlineGSK (GSK)
NCT07607925 · 49 participants (planned) · Start Jun 19, 2026 · Primary completion Jan 10, 2030
Drug: GSK5926371 · For: Lymphoma, Non-Hodgkin
Sites: Iowa City, Iowa; New York, New York; Canton, Ohio · 22 sites in all
- A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)Recruiting
GlaxoSmithKlineGSK (GSK)
NCT07371468 · 44 participants (planned) · Start Feb 10, 2026 · Primary completion Mar 15, 2028
Drug: GSK5926371 · For: Systemic Lupus Erythematosus
Sites: Buenos Aires, Argentina; San Miguel de Tucumán, Argentina; Campinas, Brazil · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Lymphoma, Non-Hodgkin
- CC-99282BMS-986369, GolcadomidePhase 37 trials
Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- valemetostat tosylateDS-3201bPhase 23 trials
Daiichi Sankyo · Non-small Cell Lung Cancer, Lung Cancer, Relapsed/Refractory Peripheral T-Cell Lymphoma
- rivogenlecleucelBPX-501 T cells, BPX-501Phase 22 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- JMBI-001Phase 21 trial
Chengdu Anticancer Bioscience, Ltd. · Advance Solid Tumors, Lymphoma, Non-Hodgkin
- JNJ-90014496Phase 21 trial
Johnson & Johnson (Janssen) · Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.